FTH — Faeth Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1829802 ·
Last close
$9.04
Market Cap
$233.63M
52W High
$42.14
52W Low
$7.45
ADV30
621,388
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -22,086,000 -20,398,000 178,949,000 14,180,000 17,852,000
Jun 2026 0 — -18,385,000 -16,007,000 189,306,000 26,903,000 16,348,000
Mar 2026 0 — -170,627,000 -170,236,000 205,381,000 152,325,000 342,667,000
Dec 2025 0 — -4,957,000 -4,717,000 22,902,000 8,668,000 4,310,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-43,272,000
Investing CF
$-137,246,000
Financing CF
$184,136,000
CapEx
$-9,000
Dividends Paid
—
Buybacks
$-16,908,000
EPS Diluted TTM
$-138.70
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-489,778,000
Inventory
—
Receivables
—
ST Investments
$160,615,000
EBIT TTM
$-215,812,000
Pretax Income TTM
$-211,358,000
Interest Exp TTM
$32,000
Analysts
13

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -22,288,000 -21,085,000 22,902,000 4,310,000 18,592,000 -20,453,000
Dec 2024 0 -31,663,000 -30,157,000 45,361,000 6,975,000 38,386,000 -24,670,000
Dec 2023 0 -37,064,000 -34,101,000 74,374,000 9,479,000 64,895,000 -32,023,000
Dec 2022 0 -50,188,000 -48,588,000 118,375,000 14,968,000 103,407,000 -39,026,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-195,528,000
OpCashFlow TTM
—
Assets (Latest)
$189,306,000
Forward EPS
$-3.67

Peers — same industry

TickerNameMarket CapLastDaily %
BIOA BioAge Labs, Inc. $234.35M $5.10 —
RCKT ROCKET PHARMACEUTICALS, INC. $235.60M $2.11 —
VNDA Vanda Pharmaceuticals Inc. $230.39M $3.81 —
ARCT Arcturus Therapeutics Holdings Inc. $229.72M $7.97 —
LFCR LIFECORE BIOMEDICAL, INC. \DE\ $242.22M $6.39 —

News headlines (Yahoo Finance, 1h cache)

Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Can
2026-11-16 12:00 · Yahoo
Faeth Therapeutics to Participate in Upcoming November Investor Conferences
2026-11-11 12:30 · Yahoo
Faeth selloff ‘disproportionate’ to data, says Lucid Capital
2026-11-10 04:50 · Yahoo
Faeth Therapeutics Plummets 42%. What Investors Are Getting Wrong, According To Analysts.
2026-11-09 21:19 · Yahoo
Faeth Therapeutics Reports 33% Response Rate in Phase 2 PIKTOR Trial for Advanced Endometrial Cancer
2026-11-09 16:00 · Yahoo
Faeth Therapeutics reports positive Phase 2 results for endometrial cancer drug
2026-11-09 12:30 · Yahoo
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
2026-11-06 21:00 · Yahoo
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-05 21:05 · Yahoo
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
2026-11-03 12:30 · Yahoo
Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout
2026-10-07 08:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.